[Influenza vaccination in immunocompromised patients]

Area of Science:

• Immunology
• Vaccinology
• Clinical Medicine

Background:

• Immunocompromised patients face heightened risks from influenza infections.
• Their compromised immune systems can lead to diminished responses after influenza vaccination.
• Studies have focused on various immunocompromised groups, including those with HIV, on rituximab or TNF-alpha blockers, with malignancies, and transplant recipients.

Purpose of the Study:

• To evaluate the immune response to influenza vaccination in diverse immunocompromised patient populations.
• To identify patient groups that may exhibit an insufficient antibody response post-vaccination.
• To assess the efficacy of adapted vaccination strategies in enhancing immune response.

Main Methods:

• Review of recent vaccination studies in immunocompromised patients.
• Analysis of antibody titres following influenza vaccination in different patient cohorts.
• Evaluation of outcomes for adapted vaccination strategies like repeated doses or higher antigen doses.

Main Results:

• Most immunocompromised patient groups achieve adequate antibody titres after influenza vaccination.
• Patients treated with rituximab, recent stem cell transplant recipients, and those on cytotoxic chemotherapy may show insufficient antibody responses.
• Adapted vaccination strategies, including repeated administration or higher antigen doses, generally improve the immune response.

Conclusions:

• Influenza vaccination is recommended for all immunocompromised patients.
• Specific patient groups may require tailored vaccination approaches to ensure an effective immune response.
• Further research into optimized vaccination strategies for vulnerable populations is warranted.